Why evidence-based medicine?

Abstract This chapter considers briefly what counts as ‘evidence’ and describes three historical strands, in medical science generally, in epidemiology and in clinical trials, that have converged to give rise to the concept of evidence-based medicine. It then returns to the randomized controlled trial as the fundamental building block of evidence-based practice. Finally, through considering whether all trials are equally useful, it demonstrates that discerning what is the best way to proceed in the clinical management of individual patients and problems is not necessarily a simple matter.

[1]  M. Bliss.  The Discovery of Insulin , 2021 .

[2]  L M Schuman,et al.  The effect of fecal occult-blood screening on the incidence of colorectal cancer. , 2000, The New England journal of medicine.

[3]  J. Vermorken.  Favourable and unfavourable effects on long-term survival of radiotherapy for early breast cancer: an overview of the randomised trials , 2000, The Lancet.

[4]  J. Danesh,et al.  Prevention of pulmonary embolism and deep vein thrombosis with low dose aspirin: Pulmonary Embolism Prevention (PEP) trial , 2000, The Lancet.

[5]  K. McLeod,et al.  Our sense of Snow: the myth of John Snow in medical geography. , 2000, Social science & medicine.

[6]  J. Colford,et al.  The impact of dosing frequency on the efficacy of 10-day penicillin or amoxicillin therapy for streptococcal tonsillopharyngitis: A meta-analysis. , 2000, Pediatrics.

[7]  S. Andriole,et al.  Rationale for randomised trials of prostate cancer screening. The International Prostate Screening Trial Evaluation Group. , 1999, European journal of cancer.

[8]  R Doll,et al.  Controlled trials: the 1948 watershed , 1998, BMJ.

[9]  R. Holman,et al.  Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. , 1998 .

[10]  C. Hennekens,et al.  Cholesterol lowering with statin drugs, risk of stroke, and total mortality. An overview of randomized trials. , 1997, JAMA.

[11]  J. Olsen,et al.  Randomised study of screening for colorectal cancer with faecal-occult-blood test , 1996, The Lancet.

[12]  D. Sackett,et al.  Evidence based medicine: what it is and what it isn't , 1996, BMJ.

[13]  D. Kromhout.  Cholesterol, diastolic blood pressure, and stroke: 13 000 strokes in 450 000 people in 45 prospective cohorts , 1995, The Lancet.

[14]  B. Haynes,et al.  Systematic Reviews: Reporting, updating, and correcting systematic reviews of the effects of health care , 1994 .

[15]  Radcliffe Infirmary,et al.  Collaborative overview of randomised trials of antiplatelet therapy - III: Reduction in venous thrombosis and pulmonary embolism by antiplatelet prophylaxis among surgical and medical patients , 1994, BMJ.

[16]  S. Genuth,et al.  The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. , 1993, The New England journal of medicine.

[17]  David Haber,et al.  Guide to clinical preventive services: a challenge to physician resourcefulness , 1993 .

[18]  D. Sackett,et al.  The Ends of Human Life: Medical Ethics in a Liberal Polity , 1992, Annals of Internal Medicine.

[19]  D. Henry,et al.  The benefits of reducing cholesterol levels: the need to distinguish primary from secondary prevention: 1. A meta‐analysis of cholesterol‐lowering trials , 1991, The Medical journal of Australia.

[20]  K. Matthews,et al.  Lowering cholesterol concentrations and mortality: a quantitative review of primary prevention trials. , 1990, BMJ.

[21]  S. Moss,et al.  Randomised controlled trial of faecal-occult-blood screening for colorectal cancer , 1989, The Lancet.

[22]  R Collins,et al.  Avoidance of large biases and large random errors in the assessment of moderate treatment effects: the need for systematic overviews. , 1987, Statistics in medicine.

[23]  R. Peto,et al.  Beta blockade during and after myocardial infarction: an overview of the randomized trials. , 1985, Progress in cardiovascular diseases.

[24]  A. Cochrane.  Sickness in Salonica: my first, worst, and most successful clinical trial. , 1984, British medical journal.

[25]  R Peto,et al.  Why do we need some large, simple randomized trials? , 1984, Statistics in medicine.

[26]  S. Greenhouse,et al.  Jerome Cornfield's contributions to epidemiology. , 1982, Biometrics.

[27]  R. Doll,et al.  Smoking and Carcinoma of the Lung , 1950, Acta - Unio Internationalis Contra Cancrum.

[28]  E. A. Graham,et al.  Tobacco smoking as a possible etiologic factor in bronchiogenic carcinoma; a study of 684 proved cases. , 1950, Journal of the American Medical Association.

[29]  L. Shattuck.  Report of the Sanitary Commission of Massachusetts 1850 , 1949 .

[30]  J. Snow.  On the Mode of Communication of Cholera , 1856, Edinburgh medical journal.

[31]  Mike Clarke,et al.  Favourable and unfavourable effects on long-term survival of radiotherapy for early breast cancer: an overview of the randomised trials , 2000 .

[32]  Stephen Inwood,et al.  The history of London , 1850 .

[33]  F. Kasten,et al.  Paul Ehrlich: pathfinder in cell biology. 1. Chronicle of his life and accomplishments in immunology, cancer research, and chemotherapy. , 1996, Biotechnic & histochemistry : official publication of the Biological Stain Commission.

[34]  Jack Cuzick,et al.  Effects of adjuvant tamoxifen and of cytotoxic therapy on mortality in early breast cancer. An overview of 61 randomized trials among 28,896 women , 1988 .

[35]  G. Smith,et al.  Medicines for the year 2000 , 1979 .

[36]  Ja Wilson,et al.  Principles and practice of screening for disease , 1968 .

[37]  T. Mckeown,et al.  An introduction to social medicine , 1966 .

[38]  Arthur Jordan,et al.  Proceedings of the Royal Society of Medicine , 1912 .